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Abstract: Background: Alow carbohydrate diet (LCD) is more beneficial for the glycometabolism in 
type 2 diabetes (T2DM) and may be effective in reducing depression. Almond, which is a common 
nut, has been shown to effectively improve hyperglycemia and depression symptoms. This study 
aimed to determine the effect of an almond-based LCD (a-LCD) on depression and 
glycometabolism, as well as gut microbiota and fasting glucagon-like peptide 1 (GLP-1) in patients 
with T2DM. Methods: This was a randomized controlled trial which compared an a-LCD with a 
low-fat diet (LFD). Forty-five participants with T2DM at a diabetes club and the Endocrine Division 
of the First and Second Affiliated Hospital of Soochow University between December 2018 to 
December 2019 completed each dietary intervention for 3 months, including 22 in the a-LCD group 
and 23 in the LFD group. The indicators for depression and biochemical indicators including 
glycosylated hemoglobin (HbA1c), gut microbiota, and GLP-1 concentration were assessed at the 
baseline and third month and compared between the two groups. Results: A-LCD significantly 
improved depression and HbA1c (p <0.01). Meanwhile, a-LCD significantly increased the short 
chain fatty acid (SCFAs)-producing bacteria Roseburia, Ruminococcus and Eubacterium. The GLP-1 
concentration in the a-LCD group was higher than that in the LFD group (p <0.05). Conclusions: A-
LCD could exert a beneficial effect on depression and glycometabolism in patients with T2DM. We 
speculate that the role of a-LCD in improving depression in patients with T2DM may be associated 
with it stimulating the growth of SCFAs-producing bacteria, increasing SCFAs production and 
GPR43 activation, and further maintaining GLP-1 secretion. In future studies, the SCFAs and GPR43 
activation should be further examined. 
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1. Introduction 
Type 2 diabetes mellitus (T2DM) is a heterogenous set of disorders characterized by 
glycometabolism abnormalities. According to a report of the International Diabetes Federation (IDF), 
there are currently around 415 million people with diabetes worldwide, a figure likely to increase to 
629 million by 2045 [1]. Diabetes is associated with several complications such as mental health-
related disorders, particularly depressive disorders [2]. A meta-analysis revealed that the prevalence 
of depression in patients with diabetes was considerably higher than in non-diabetic subjects (17.6% 
vs. 9.8%) [3].Furthermore, epidemiological evidence indicated that patients with T2DM are almost 
three times as likely to be affected by depression compared with the general population [4]. A 
bidirectional relationship exists between T2DM and depression; depression increases the risk of the 
development of T2DM and the subsequent risks of hyperglycemia, insulin resistance, and micro and 
macro vascular complications. Conversely, a diagnosis of T2DM increases the risk of incident 
depression and can contribute to a more severe course of depression [2]. The American Diabetes 
Association (ADA) [5] and IDF [6] emphasize that: management of mental health is an important 
aspect of diabetes treatment. However, the tricyclic antidepressant commonly used in clinical practice 
has an adverse effect on glucose homeostasis control by reducing the insulin secretory rate [7]. 
Medical nutrition therapy is an essential measure to prevent and control diabetes at any stage of 
its natural course, and it improves blood glucose by regulating the nutrient and energy intake. 
Nevertheless, most available nutritional therapy mainly focuses on improving glycometabolism, and 
little attention is paid to improving the depression in T2DM patients. In China, low-fat diet (LFD) is 
recommended by Guideline for prevention and control of type 2 diabetes in China (2017 Edition)to 
help improve blood glucose levels in patients with T2DM[8]. However, a meta-analysis which 
included a total of nine studies and pooled results suggested a reasonable low-carbohydrate diet 
(LCD) is more beneficial for T2DM [9]. LCD refers to a dietary strategy that reduces the energy supply 
ratio of carbohydrates and increases the energy supply ratio of fats and proteins [10]. According to 
the energy supply ratio of carbohydrates, it can be divided into two modes: very low LCD (<26%), 
LCD (26~45%) [11]. 
In terms of the relationship between the proportion of carbohydrate intake and depression, the 
results remain controversial. Most studies support a protective effect of a low fat-high carbohydrate 
diet on depression. Pellegrin et al. [12] showed that daily carbohydrate intake was negatively 
correlated with depression score (R = −0.33, p <0.01) in obese women. Deijen et al. [13] found that 
long-term consumption of LCD would aggravate negative psychology such as depression. A 
randomized controlled trial (RCT) by Rosenthal et al. [14] showed that a carbohydrate-rich meal 
could reduce depression level in patients with seasonal affective disorder. However, for T2DM 
patients, carbohydrate is by far the greatest dietary contributor to blood glucose rise, as expected, 
dietary carbohydrate restriction reliably reduces glucose profile [9]. So, it is crucial to explore a diet 
regimen that is beneficial to both depression and glycometabolism. 
Nuts as part of LCD have been shown to effectively improve glycosylated hemoglobin (HbA1c) 
levels and fasting blood glucoses (FBG) in T2DM patients [15]. In addition, the synergy and 
interaction of all the nutrients and other bioactive components in nuts have a beneficial effect on 
brain, cognition, and neuropsychiatric disorders [16,17]. Various interventions [18,19], along with 
two recently published cohort studies [20,21], have found higher nut consumption was associated 
with lower depression scores. A cohort study in Tianjin, China indicated that nut consumption may 
be beneficial in the prevention of depressive symptoms [21]. In a large, parallel-group, multicenter, 
RCT using a Mediterranean diet supplemented with 30 g mixed nuts (15 g walnuts, 7.5 g hazelnuts, 
and 7.5 g almonds) including 7447 participants for 3 years, the result indicated that the inverse 
association with depression was not significant (RR = 0.78, 95% CI 0.55–1.10) in the whole cohort. 
However, when the analysis was restricted to participants with T2DM, a 40% lower risk of depression 
in participants with T2DM (RR = 0.59, 95% CI 0.36–0.98) was reported [18]. 
Almond is the most consumed and studied nut. It possesses potential prebiotic properties; its 
ingestion leads to an improvement in the gut microbiota profile and a modification of the gut 
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microbiota activities [22].The study of Liu et al. [23] indicated that almond supplementation could 
significantly increase the populations of Bifidobacterium and Lactobacillus, which may potentially 
contribute to increased production of short-chain fatty acids(SCFAs) [24].SCFAs are the ligand of G 
protein-coupled receptor43 (GPR43), and its combination with GPR43 can promote the secretion of 
glucagon-like peptide 1 (GLP-1) [25]. GLP-1 is an important regulator of microbiota–gut–brain 
signaling in health and stress-related psychiatric illnesses, which has been proven to have 
antidepressant effect [26]. 
In our previous preliminary study, we replaced 150 g/d staple food with 56 g/d almond to form 
an almond-based LCD (a-LCD) [15]. There are very few studies that have explored the role of a-LCD 
on both the depression and glycometabolism in T2DM patients. Based on the above, we hypothesized 
that a-LCD could improve depression and glycometabolism in patients with T2DM through 
modulating gut microbiota and GLP-1. In this study, we further explored the effect of a-LCD on the 
depression, HbA1c, gut microbiota and GLP-1. 
2. Materials and Methods 
2.1. Study Design 
This was a 3-month, prospective RCT performed at a diabetes club and the Endocrine Division 
of the First and Second Affiliated Hospital of Soochow University from December 2018 to December 
2019. The recruited participants were randomly allocated to either an intervention or control group 
using a table of computer-producing random numbers. The random numbers were concealed by 
someone who was not responsible for this study, so both the researcher and the participants were 
blinded prior to assignment. Before intervention, all participants underwent a one-week washout 
period to diminish the effect of background diets[27]. In this regard, participants who met the 
inclusion criteria were asked to stop eating nuts for >4 d/w before the intervention. This study 
followed the Declaration of Helsinki and the Guidelines for Good Clinical Practice and was approved 
by the ethics committee of the Soochow University (No. 2019000147). All enrolled patients signed 
consent form. The Randomized Controlled Trial Registration number for the study 
is ChiCTR1900024407. 
2.2. Study Participants 
Inclusion criteria of this study were as follows: patients (1) had been diagnosed with T2DM; (2) 
were older than 18 years; (3) had no change in oral anti-diabetic drugs or insulin in half a month 
before the intervention; (4) were able to communicate with others; (5) had volunteered to participate 
in this study, and (6) were able to provide informed consent. Patients were excluded from this study 
if they (1) ate nuts regularly (>4 days/week) [28]; (2) were allergic to nuts or received other dietary 
interventions; (3) had difficulty in chewing nuts; (4) had severe conditions including digestive 
dysfunction, heart failure, renal failure, malignant tumors, severe cerebrovascular diseases, ketosis, 
hyperthyroidism, liver dysfunction, or severe gallbladder and pancreatic diseases; (5) their FBG were 
more than 16.7 mmol/L [15];(7) suffered from mental illness; (8) used anti-depressant, anxiety, 
neurological or psychiatric medication [29]; (9) pregnant or lactating [29]; (10) used GLP-1 receptor 
agonists or Dipeptidyl Peptidase-4 (DPP-4) inhibitors;(11) regularly took glucocorticoids;(12) 
regularly took antibiotics, supplementations (e.g., prebiotics) and yogurt within 3 weeks which were 
known to alter gut microbiota [30]. Patients were withdrawn from the study if the following occurred: 
patients (1) ate almond <4 d/w (56 g/d) in the a-LCD group and ate almond in the LFD group >2d/w 
(56 g/d); (2) were unable to follow the diet plan; (3) suffered from major life events; (4) had adverse 
effect occurred during the intervention (e.g., intolerance to almonds). 
2.3. Sample Size Calculation 
Evidence from the literature showed that the mean difference of the changes in the depression 
score was 2 between the LCD and the LFD group [31]. Therefore, we calculated 23 participants for 
Nutrients 2020, 12, 3036 4 of 21 
 
each group, with α = 0.05 and power = 0.80. Considering the 10% sample loss rate, the increase of 
sample size according to the actual situation is expected to be 25 cases in each group. 
2.4. Intervention 
The control group adopted an LFD education program which is a named six-point formula [15] 
developed by our research team based on the diabetes dietary guideline. The detailed contents of the 
six-point formula included: 1 jin vegetables/days; 2 liang staple food/meal (300 g/day); 3 tablespoons 
of oil/day; eating fruits under 4 conditions (stable glycemia, low glycemic index fruit, between two 
meals, adding energy fruit provided to the total calories); 5 kinds of protein food/day (1 carton of 
milk (220 mL), 1 egg, 1 liang fish or shrimp, 1 liang soybean production, 1 liang meat); 6 g salt/day. 
The a-LCD group consumed 56 g/day almond which replaced 150 g/d staple food (1 liang staple 
foods/meal) that is rich in carbohydrate, and the remaining of the dietary regimen kept the same as 
those of LFD. Almonds were uniformly purchased, weighed, vacuum-packed, and distributed every 
two weeks. The participants were instructed to consume almonds between meals or with breakfast, 
or when hungry. For those whose FBG were higher than normal (>6.1 mmol/L), the almonds were 
required to be consumed before 10:00 a.m. [32]. The participants were instructed to consume 50% of 
the nuts before bedtime if there was a risk of a nocturnal hypoglycemic event. Participants were 
followed up once a week, including where we: collected the information about the implementation 
of dietary regimen and almond adherence to understand the dietary adherence; strengthened their 
compliance and excluded participants with poor compliance; collected information of anti-diabetics; 
asked if they had any adverse reactions, hypoglycemic events, and major life events. 
2.5. Outcomes 
2.5.1. Glycated Hemoglobin (HbA1c) 
Blood samples were obtained to measure HbA1c at the nursing School of Soochow University 
and measured by high-performance liquid chromatography using Afinion AS100 Analyzer (Alere, 
Inc., Shanghai, China) in the molecular laboratory of the nursing school of Soochow University. 
2.5.2. Depression 
Depression score was assessed through PROMIS short form v1.0-Depression 8b [33], which are 
universal rather than disease-specific. The PROMIS Depression item banks assess self-reported 
negative mood (sadness, guilt), views of self (self-criticism, worthlessness), and social cognition 
(loneliness, interpersonal alienation), as well as decreased positive affect and engagement (loss of 
interest, meaning, and purpose). Our team investigated local patients with T2DM and found that its 
cronbach’s α was 0.879. The total scores ranged from 37.1 to 81.1 points. The higher the score of the 
scale, the more serious the depressive symptoms. 
2.5.3. Anthropometric Measurements 
The weight and height were measured bya unified measuring device at the nursing school of 
Soochow University.Body mass index (BMI) was calculated as weight (in kilograms) divided by 
height (in meterssquared). 
2.5.4. Dietary Record 
Patients maintained a dietary record, including a detailed diet of one day of the weekend and 
two working days, and then Feihua nutrition software V2.72 version (Bowen Shixun Technology, Beijing, 
China) was used to calculate the proportion of three macro-nutrients per day to evaluate the 
implementation of the dietary plan of the subjects. An almond adherence record table was used to 
measure the compliance of almond intake, and consumption ≥4 days/week indicates good 
compliance. 
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2.5.5. Fasting GLP-1 Concentration 
GLP-1 was measured byenzyme-linked immunosorbent assay (ELISA). The fasting peripheral 
venous blood of participants was collected by vacuum blood vessels containing EDTA 
anticoagulants, DPP-4 inhibitors were added immediately after blood collection at bedside to prevent 
GLP-1 degradation. The blood samples were centrifuged at 2~8 °C 1000× g for 15 min within 30 min 
after collection and thesupernatant was retained and stored at −20 °C or −80 °C, but repeated freeze-
thaw was avoided. 
2.5.6. Gut Microbiota 
The fecal specimens of all participants were taken. Researchers instructed the participants to put 
the feces on the thick sterile pad. The sterile cotton swab was used to take about 20 g fresh fecesfrom 
participants into the sterile feces collection tubes. After the specimen was collected, it was 
immediately put into the portable liquid nitrogen tank and frozen for 15 min. The specimens were 
transferred to the −80 °C refrigerator within 24 h for preservation. For each fecal specimen, DNA was 
extracted and purified, and the V3-V4 region of the 16S rRNA genes was polymerase chain reaction 
(PCR)-amplified using modified universal bacterial primers [34]. Purified PCR products were 
sequenced with the Hiseq2500 PE250 platform [35]. Sequence data were compiled and processed 
using QIIME [36]. Sequence data were screened and filtered for quality and then aligned to the full-
length 16S rRNA gene, using the SILVA reference alignment as a template [37]. Sequences were 
grouped into operational taxonomic units (OTUs) of 97% similarity. Phylogenetic classification was 
used to describe the intestinal composition of each participant [38]. The following alpha-diversity 
measures were assessed:(1)Chao1 index, a measure of species richness that is particularly applied to 
low abundance datasets; (2) Faith’s Phylogenetic Diversity (Faith’s PD), the most commonly used 
measure of phylogenetic diversity. The principal co-ordinates analysis (PCoA) of the weighted 
Unifrac (quantitative, i.e., weighs branches of phylogenetic tree based on abundance) distances was 
used to compare the overall microbiota structures in the two groups. 
2.6. Statistical Analysis 
A statistical analysis was performed using SPSS 25.0 software (SPSS, Inc., Chicago, IL, USA). For 
continuous variables, the results were described as the mean ± standard deviation (SD) and 
comparisons were performed using Independent Samples t-test, Paired Samples t-test or the Mann–
Whitney U test, and Wilcoxon rank-sum test. For categorical variables, the results were presented as 
frequency (percentages); comparisons between groups were made using the Chi-squared test. To 
eliminate the problem of confounding factors, the comparisons of outcomes between the groups after 
the intervention were performed using a covariance analysis (covariate: age, protein, baseline level 
for depression and HbA1c, the rate of change of anti-diabetics).The intention-to-treat (ITT) of 
depression and HbA1c were performed so as to ensure the reliability of the research results. The 
proportion of three macro-nutrients in relation to energy supply, representing participants’ dietary 
adherence, which were assessed once a week during the intervention have been presented as a pie 
chart. The comparisons of gut microbiota between two groups were evaluated with theMann–
Whitney U test, within group differences were analyzed using Wilcoxonrank test. A p value of <0.05 
was considered statistically significant. A corrected false discovery rate (FDR) <0.2 was considered as 
significant [39]. 
3. Results 
3.1. Study Participants 
On the basis of inclusion and exclusion criteria, 50 participants with T2DM were recruited and 
randomly allocated to the a-LCD group (n =25) and the LFD group (n =25). Three participants (1 who 
did not like almond, 2 with difficulty chewing) in the a-LCD group and two participants (1 who ate 
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almond <4 day/week, another who was lost during follow-up) in the LFD group withdrew from the 
study. Finally, the data of 22 participants in the a-LCD group and 23 in the LFD group were analyzed 
(Figure 1). The mean age of participants was (71.98 ± 5.63 years) and 25 (55.6%) were female. The 
general characteristics of the enrolled participants in each group are shown in Table 1. There were no 
statistically significant differences in any of the parameters between the two groups (p >0.05). 
 
Figure 1. Flow diagram of the participants included in the study.(a-LCD (almond-based low 
carbohydrate diet); LFD (low fat diet). 
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Table 1. Baseline characteristic. 
Variables  a-LCD (n =22) LFD (n =23) t/χ2/Z p 
  
x ± SD/n(%)/ 
M(P25,P50) 




Age (years)  73.55 ± 4.99 70.48 ± 5.91 −1.877 a 0.067 
Gender-male  9(40.9%) 11(47.8%) 0.218 b 0.641 
Marital status (married)  20(90.9%) 21(91.3%) 0.002 c 0.963 
Education Primary and below 2(9.1%) 2(8.7%) 4.037 b 0.258 
 Journal high school 4(18.2%) 10(43.5%)   
 Technical and senior high school 11(50.0%) 9(39.1%)   
 Journal college school and above 5(22.7%) 2(8.7%)   
Payment Medical insurance 22(100%) 21(91.3%) 2.002 c 0.157 
Monthly income (thousand yuan) <2 0(0%) 3(13.0%) 3.950 b 0.139 
 2~5 19(86.4%) 15(65.2%)   
 ≥5 3(13.6%) 5(21.7%)   
Occupation status Retire 22(100%) 22(95.7%) 0.978 c 0.323 
 On the job 0(0%) 1(4.3%)   
Residential status Living by oneself 2(9%) 2(8%) 0.311 b 0.856 
 Living with spouse 19(86%) 19(83%)   
 Living with children 1(5%) 2(9%)   
Exercise intensity (d) Low intensity  19(86.4%) 18(78.3%) 0.505 b 0.477 
 Moderate intensity 3(13.6%) 5(21.7%)   
Exercise time/(minute)  315.00(210.00,420.00) 360.00(210.00,420.00) −0.537 d 0.591 
Clinical data 
Smoking (Yes)  1(4.5%) 2(8.7%) 0.311 c 0.577 
Drinking (Yes)  4(18.2%) 3(13.0%) 0.226 c 0.634 
Diabetes duration (years)  14.18 ± 7.06 15.65 ± 7.02 0.700 a 0.487 
Family history of diabetes (Yes)  12(54.5%) 11(47.8%) 0.203 b 0.652 
Diabetic complication (Yes)  9(40.9%) 11(59.3%) 0.573 b 0.449 
Accompanying disease (Yes)  16(72.7%) 17(73.9%) 0.008 b 0.928 
Therapy method None 1(4.5%) 1(4.3%) 1.825 b 0.610 
 Only Hypoglycemic drugs 12(54.5%) 14(60.9%)   
 Only Insulin 1(4.5%) 3(13.0%)   
 Hypoglycemic drugs + insulin 8(36.4%) 5(21.7%)   
Number of combination medication 0 2(8.7%) 4(14.8%) 5.022 b 0.170 
 1 8(34.8%) 4(14.8%)   
 2 13(56.5%) 16(59.3%)   
 3 0(0%) 3(11.1%)   
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U. M(P25,P50): median (25th and 75th percentile). 
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3.2. Dietary Adherence 
3.2.1. Proportions of Calories from Three Macro-Nutrients the Patients Consumed 
The results of the three macro-nutrients allocated between the a-LCD and the LFD group based 
on three days diet record showed that at the baseline, the total energy and the proportions of calories 
from the three macro-nutrients were not significantly different between the two groups. At the third 
month, the total energy was not significantly different between the two groups. However, compared 
to the LFD group, the calories from carbohydrates decreased, while those from fat significantly 
increased in the a-LCD group (p <0.01) (Table 2). In addition, after the intervention, the percentage of 
the calories from carbohydrates (40%) met the standard of LCD in the a-LCD group, while the calories 
from fat (25%) met the standard of LFD in the LFD group (Figure 2). 
Table 2. Comparison of the calories from three macro-nutrients consumed by the patients. 
 Variables a-LCD (n =22) LFD (n =23) t p 
Baseline 
Total calorie intake/day 1686.34 ± 231.25 1781.91 ± 280.91 −1.232 0.184 
Carbohydrate-calorie (Kcal) 974.95 ± 148.22 1007.61 ± 136.32 −0.761 0.504 
Fat-calorie (Kcal) 406.76 ± 143.88 478.29 ± 149.97 −1.614 0.085 
Protein-calorie (Kcal) 318.45 ± 63.19 292.38 ± 65.12 1.348 0.524 
Third month 
Total calorie intake/day 1642.08 ± 227.74 1764.77 ± 297.40 −1.536 0.114 
Carbohydrate-calorie (Kcal) 673.14 ± 91.80 1042.10 ± 195.41 −8.016 <0.01 ** 
Fat-calorie (Kcal) 648.19 ± 128.93 433.01 ± 137.39 5.357 <0.01 ** 
Protein-calorie (Kcal) 372.03 ± 64.45 288.94 ± 64.34 1.962 0.067 
PValue for comparison by independent sample t-test. **: p <0.01. 
  
Figure 2. Three macro-nutrient energy supply ratios of two groups after intervention. 
3.2.2. Almond Adherence 
The almond adherence of the a-LCD group is shown in Figure 3. A fold line diagram was 
performed to describe the changing trend of almond adherence in the a-LCD group. The result 
indicated that the frequency of almond consumption was stable and good. 
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Figure 3. The changing trends of almond adherence in the a-LCD group. 
3.3. Effect of a-LCD on Glycated Hemoglobin (HbA1c) 
At the baseline, HbA1c levels were not significantly different between the two groups. 
Compared to the baseline, HbA1c levels in both groups decreased significantly (p <0.01, p <0.05) 
during the study period. At the third month, the HbA1c level in the a-LCD group decreased more 
than that in the LFD group (p <0.01, Table 3). The ITT, in relation to HbA1c levels, was performed to 
ensure the stability of the above results. The result of ITT was found to be in agreement with the 
findings above (Supplementary Table S1). 
Table 3. Comparison of glycated hemoglobin (%) between the two groups. 
Study Period a-LCD (n =22) LFD (n =23) t/F p 
Baseline 7.67 ± 1.60 7.54 ± 1.31 −0.287 a 0.776 
Third month 6.85 ± 1.02 (adjusted:6.77 ± 0.13) 7.37 ± 1.29 (adjusted:7.44 ± 0.12) 14.111 b <0.01 ** 
t 4.081 c 2.614 c   
p <0.01 ** 0.016*   
a Independent-samples T test for between-groupdifferencesat the baseline; bcovariance analysis for 
between-groupdifferences at the third month, with adjusted data presented as mean ± standard error 
(covariate: age, baseline HbA1c, protein, the rate of change of anti-diabetics); cpaired sample T test for 
within-group difference. * p < 0.05; ** p < 0.01. 
3.4. Effect of a-LCD on the Changes of Anti-Diabetics 
During the intervention, three in the LCD group and five in the LFD group had anti-diabetic 
dosage reduced, while the other participants remained unchanged, but there was no significant 
difference between the two groups in the third month (p >0.05, Table 4) 
Table 4. Comparison of other anti-diabetic drugs between the two groups. 
 a-LCD (n = 22) LFD (n = 23) χ2 p 
Reduction 3(14%) 5(22%) 0.019 0.889 
No change 19(86%) 18(78%)   
Pvalue for comparison between treatments diets by Chi-square test. 
3.5. Effect of a-LCD on Weight and BMI 
At the third month, weight and BMI showed no significant difference between thetwo groups(p> 
0.05, Table 5). Compared to the baseline, weight and BMI of a-LCD group improved significantly at 
the third month (p <0.05, Table 5). 
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Table 5. Comparison of weight and BMI between the two groups. 
Variables  a-LCD (n = 22) LFD (n = 23) t p 
Weight (Kg) Baseline 66.60 ± 8.81 63.07 ± 12.88 0.784 a 0.459 
 Third month 59.34 ± 8.90 62.58 ± 13.12 0.967 a 0.339 
 t 2.164 b 1.397b   
 p 0.042 * 0.176   
BMI (Kg/m2) Baseline 23.53 ± 2.33 23.69 ± 2.83 0.216 0.830 
 Third month 23.02 ± 2.45 23.53 ± 3.04 0.641 0.524 
 t −2.261 −1.283   
 p 0.034 * 0.211   
p value for comparison between two groups by Independent Samples t-test and paired sample T test.a 
Independent-samples T test for between-groupdifferencesat the baseline and third month; bpaired 
sample T test for within-group difference. * p < 0.05. 
3.6. Effect of a-LCD on Depression 
At baseline, the depression scores were not significantly different between the two groups. 
Compared to the baseline, depression score in the a-LCD group decreased significantly (p <0.01) in 
the third month, while there was no decrease in the LFD group (p >0.05). At the third month, the 
depression score in the a-LCD group was significantly lower than that in the LFD group (p <0.01, 
Table 6). The ITT, in relation to depression scores, was performed to ensure the stability of the above 
results. The ITT result was found to be in agreement with the earlier findings (Supplementary Table 
S2). 
Table 6. Comparison of depression scores between the two groups. 
Study Period a-LCD (n = 22) LFD (n = 23) t/F p 
Baseline 48.41 ± 8.05 49.57 ± 8.46 0.471 a 0.640 
Third month 42.07 ± 5.80(adjusted:42.58 ± 0.89) 48.65 ± 7.69(adjusted:48.16 ± 0.87) 19.308 b <0.01 ** 
t 6.196 c 0.838 c   
p <0.01 ** 0.411   
a Independent-samples T test for between-group differencesat the baseline; bcovariance analysis for 
between-group differences at the third month, with adjusted data presented as mean ± standard error 
(covariate: age, baseline depression scores, protein); cpaired sample T test for within-group difference. 
* p < 0.01. 
3.7. Fasting Plasma GLP-1 Concentration 
Compared to the baseline, we found that GLP-1 did not significantly change in both groups at 
the third month. However, GLP-1 in the a-LCD group was significantly higher than that in the LFD 
group after intervention (p <0.05). (Table 7) 
Table 7. Comparison of GLP-1[M(P25,P75)], (pmol/L)]in the two groups. 
Study Period a-LCD (n =22) LFD (n =23) Z p 
Baseline 1.381 (0.697,3.157) 1.190 (0.804,1.896) −0.409 0.683 
Third month 1.092 (0.886,2.671) 0.630 (0.261,1.997) −2.396 0.017 * 
Z −0.221 −1.339   
p 0.833 0.162   
Z-value and p-value for comparisons by Mann–Whitney U or Wilcoxon for between or within group 
differences at the baseline and third month, the result presented as M(P25, P75). * p < 0.05; M(P25,P50): 
median (25th and 75th percentile). 
3.8. Gut Microbiota 
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A total of 2,981,481 quality reads of 90 samples were generated with an average of 33,128 ± 2868 
reads per sample. 
3.8.1. Alpha-Adversity 
The alpha-diversity of the gut microbiota community indicated that compared with the baseline, 
the Chao 1 and PD index of both groups increased significantly (p< 0.01) (Supplementary Figures S1 
and S2). 
3.8.2. Beta-Diversity 
The PCoA of the weighted Unifrac distances was used to compare the overall microbiota 
structures in the two groups and the results are shown in Supplementary Figures S3 and S4.The more 
similar the samples of community microbials are, the closer they are to each other.The result revealed 
there was no extremelyapparent separation in gut microbiota structure between and within the 
groups at the baseline and the third month. 
3.8.3. The Comparison of the Composition of Gut Microbiota in the Two Groups 
The overall microbial compositions between two groups at baseline and three months are shown 
in the Figures 4 and 5. To determine if the a-LCD affected the gut microbiota, we compared the 
composition of gut microbiota in the two groups at baseline and the third month (Table 8). At the 
phylum level, Firmicutes in the a-LCD group was significantly lower than that in the LFD group by 
the third month (p <0.05, FDR = 0.026). Compared to the baseline, Bacteroidetes (p <0.05, FDR = 0.016) 
decreased significantly in the a-LCD group. At the genus level, Roseburia (p <0.01, FDR <0.01,) and 
Ruminococcus(p <0.05, FDR = 0.073)in the a-LCD group were significantly higher than those in the 
LFD group by the third month; compared to the baseline: Eubacterium(p <0.01, FDR = 0.013), Roseburia 
increased significantly(p <0.05, FDR = 0.021) and Bacteroides(p <0.05, FDR = 0.013)decreased 
significantly in the a-LCD group. 
     
Figure 4. The comparison of the overall microbial composition between the two groups at the 
baseline. Only taxonomic groups 1% or greater are shown. 
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Figure 5. The comparison of the overall microbial composition between the two groups at the third 
month. Only taxonomic groups 1% or greater are shown. 
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Table 8. Comparison of the composition of gut microbiota [M(P25,P75)] in the two groups. 
Phylum Genus Study Period a-LCD (n =22) LFD (n =23) Z p(adj. val.) 
Firmicutes  Baseline 0.389(0.283,0.729) 0.544(0.455,0.671) −1.317 0.188(0.194) 
  Third month 0.580(0.371,0.672) 0.684(0.561,0.778) −2.317 0.021*(0.026) 
  Z −1.282 −2.281   
  p(adj. val.) 0.200(0.213) 0.023 *(0.038)   
 Roseburia Baseline 0.002(0.000,0.005) 0.009(0.005,0.024) −1.892 <0.01 **(<0.01) 
  Third month 0.005(0.000,0.006) 0.000(0.000,0.001) −2.626 <0.01 **(<0.01) 
  Z −2.193 −4.075   
  p(adj. val.) 0.028 *(0.021) <0.01 **(<0.01)   
 Eubacterium Baseline 0.008(0.004,0.0220) 0.037(0.018,0.070) −3.747 <0.01 **(<0.01) 
  Third month 0.026(0.004,0.057) 0.042(0.024,0.099) −2.082 0.037*(0.073) 
  Z −2.678 −1.734   
  p(adj. val.) <0.01 **(0.013) 0.083(0.052)   
 Ruminococcus Baseline 0.017(0.011,0.033) 0.020(0.005,0.037) −0.829 0.470(0.407) 
  Third month 0.026(0.005,0.044) 0.005(0.000,0.019) −2.015 0.044*(0.073) 
  Z −0.341 −2.312   
  p 0.733(0.308) 0.021 *(0.020)   
 Lactobacillus Baseline 0.007(0.003,0.049) 0.005(0.002,0.012) −1.420 0.156(0.223) 
  Third month 0.007(0.000,0.068) 0.000(0.000,0.047) −1.666 0.096(0.245) 
  Z −1.150 −0.973   
  p(adj. val.) 0.130(0.073) 0.330(0.167)   
Bacteroidete
s 
 Baseline 0.249(0.120,0.323) 0.110(0.072,0.180) −2.793 <0.01 **(0.011) 
  Third month 0.151(0.061,0.256) 0.108(0.042,0.236) −0.591 0.555(0.415) 
  Z −2.451 −1.004   
  p(adj. val.) 0.014 *(0.016) 0.361(0.188)   
 Bacteroides Baseline 0.144(0.057,0.256) 0.047(0.023,0.119) −3.244 <0.01 **(<0.01) 
  Third month 0.064(0.027,0.106) 0.057(0.009,0.085) −0.978 0.328(0.364) 
  Z −2.354 −0.335   
  p(adj. val.) 0.019*(0.013) 0.735(0.308)   
Z-value and p-value for comparisons by Mann–Whitney U or Wilcoxon for between or within group differences at the baseline and third month, the result presented 
as M (P25,P75). * p < 0.05; ** p < 0.01; M(P25,P50): median (25th and 75th percentile).P value (adj. val.), FDR <0.2 was considered as significant. 
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4. Discussion 
Until now, only few studies have reported whether a diet regimen is beneficial to both 
depression and glycometabolism in T2DM patients. Almond is rich in some nutrients and it may be 
protective against the development of depression.Based on our previous study of a-LCD improving 
glucose [15], we further explored the effect of this diet regimen on both depression and 
glycometabolism in T2DM patients. 
4.1. Effect of a-LCD on Glycemic Control and Anti-Diabetics 
For diabetes patients with depression, the primary clinical concern is still on the control of 
glycometabolism. HbA1c level can reflect mean blood glucose level over the last 8–12 weeks and 
long-term glycemic control of T2DM patients [8]. It could be used as the main indicator to establish 
glycemic control. Over 3 months, our study found that both a-LCD (p <0.01) and LFD (p <0.05) 
improved HbA1c level, while better HbA1c level was seen in the a-LCD group(p <0.01), which is 
consistent with our previous research [15].Although there was no significant difference inanti-
diabetics between the two groups during the three-month period, three in the a-LCD group and five 
in the LFD groupreduced the dosage of anti-diabetic drugs. After controlling the rate of change of 
anti-diabetics as a covariate, the HbA1c in the a-LCD group was still significantly lower than that in 
the LFD group, indicating that the hypoglycemic effect of LCD was better than that in the LFD group. 
The reasons for the potential benefit of a-LCD on HbA1c were shown in those studies [15,27]. 
4.2. Effect of a-LCD on Weight and BMI 
Nuts have rich energy density and high fat[40], the greater fat availability may reduce gastric 
emptying rate to increase the satiety [41]. In this study, a-LCD decreased weight (p <0.05) and BMI (p 
<0.05) of patients with T2DM, further confirming the effectiveness of LCD in improving weight and 
BMI. The results are in agreement with the result of our previous study and the reason for the 
potential benefit of a-LCD on weight and BMI were shown in  that study [15]. 
4.3. Effect of a-LCD on Depression Score 
The impact of LCD on depression is controversial. Brinkworth et al. [42] used monounsaturated 
and polyunsaturated fat instead of carbohydrate to form LCD and assessed the effect of LCD on 
psychological mood state and well-being in obese patients with T2DM. The results found that the 
Beck Depression Inventory Score declined over time in theboth LCD and LFD groups (p <0.05). 
Saslow et al. [43] assessed the effect of a 3-month LCD (lower their carbohydrate consumption and 
derive their remaining calories from fat) and a LFD on psychological outcomes in obesity/overweight 
patients with T2DM or pre-diabetes. No significant differences in depression scores were observed 
between the two groups (p >0.05). In the current study, we found that a-LCD significantly decreased 
the depression score compared to LFD (p <0.01) in patients with T2DM, which is not consistent with 
the findings in above-mentioned studies. The important reason for the inconsistent effect of LCD on 
depression may be due to the difference in the composition of the food for LCD. A major difference 
was that we used almond to replace carbohydrate. Almond as a commonly eaten nut, is a rich source 
of dietary fiber, polyphenols, and unsaturated fatty acids [44], that may be protective against the 
development of depression [45–47]. With regard to the association of nuts intake and mental health, 
most of studies showed the positive effect of nuts. In the PREDIMED trial, an RCT with the 
Mediterranean diet supplemented with nuts showed a 40% lower risk of depression in patients with 
T2DM (RR = 0.59, 95% CI 0.36–0.98) [18]. An RCT conducted by Pribis et al. [19] explored the effect 
of walnut consumption on mood in young adults and observed a significant medium effect size 
improvement in the Total Mood Disturbance Score (−27.5%, p =0.043) in males. Another reason for 
the inconsistent results with other studies may be the different participants in their studies who were 
obese. 
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4.4. Effect of a-LCD on Regulation of Gut Microbiota and GLP-1 Expression 
In our study, the a-LCD and LFD at 3 months increased Chao1 and PD index in the two groups, 
although there were no significantdifferences between the two groups. Increased microbiome 
diversity could promote greater stability of the microbiome in the long term, thereby contributing to 
functional resilience against extreme stress and perturbations [48]. 
Currently, there are no reports of gut microbiota in T2DM with depression, but there is evidence 
of significant differences between depressed patients and healthy people [49]. Jiang et al. [49] 
compared the composition between depressed patients with healthy people, and the result indicated 
that, at the phylum level, depressed patients had higher population of Bacteroidetes. After the 
intervention of the a-LCD, we observed the changes of the above-mentioned bacteria. At the phylum 
levels, Bacteroidetes decreased significantly in the a-LCD group. We also found that a-LCD for 3 
months decreased the population of the pathogenic bacterium Bacteroides, which is consistent with 
the study of Dhillon et al. [50]. The above result show that a-LCD could regulate the gut bacteria and 
the improvement of depression score in the a-LCD may be through modulating of the microbiome-
gut-brain. 
A growing understanding of the microbiome-gut-brain connections is revealing the pathways 
by which food choices may affect depression [51], and GLP-1 is an important regulator of microbiota-
gut-brain signaling in health and stress-related psychiatric illnesses [26]. Almonds are a rich source 
of fiber, unsaturated fats, and polyphenols, all nutrients that can favorably alter the gut microbiome 
[50] and its consumption increases the number of SCFAs-producing bacteria [23]. SCFAs in 
combination with GPR43 can promote the secretion of GLP-1 [25]. GLP-1, produced both in 
peripheral L-cells of the gastrointestinal tract and in the brain, is an anorexigenic peptide and 
treatment target for T2DM [26]. GLP-1 analog liraglutide has been recently reported to attenuate 
depressive behaviors via improving hippocampal plasticity in mice [52]. GLP-1 receptor agonists 
have also been shown to have neuroprotective effects both in diabetic [53] and depressed [54] mice. 
The study of Grant et al.[55] showed that a depression and anxiety score generally tends to improve 
in GLP-1 analog exenatide-treated T2DM patients and it could be used as an adjunctive therapy for 
depression in diabetes. 
An important finding of the present study was that the a-LCD significantly increased the relative 
abundance of SCFAs-producing bacteriaRoseburis [24] (p <0.01, FDR <0.01)and Ruminococcus [24](p 
<0.05, FDR = 0.073), which is consistent with the study by Holscher et al. [56], where they found that 
almond consumption increased the Roseburia (p<0.05). Compared to the baseline, SCFAs-producing 
bacteria Roseburia (p <0.05, FDR = 0.021) and Eubacterium (p <0.01, FDR = 0.013) were significantly 
increased in the a-LCD group. However, other studies found that almond consumption also 
increased the population of SCFAs-producing bacteria Bifidobacterium and Lactobacillus [23], although 
these were not consistent with our findings, which may be due to the differences in ethnicity [57]. 
Research has indicated that GLP-1 levels decrease significantly in the T2DM patients [58]. In our 
study, GLP-1 concentration decreased at the third month compared to the level of the baseline, 
although there were no statistical differences. However, it is worth noting that GLP-1 concentration 
in the LCD group was significantly higher than that in the LFD group in the third month (p<0.05), 
indicating a-LCD maintained the GLP-1 secretion. An RCT randomly assigned a trial diet with 28 g 
almonds or without almonds and the result indicated that the rise in GLP-1 concentration at 30 min 
post-meal was due to the effect of almond ingestion for both non-diabetic and T2DM groups 
[59].Based on the results of this study, we speculate that the role of a-LCD in improving depression 
in patients with T2DM may be associated with it stimulating the growth of SCFAs-producing 
bacteria, then increasing SCFAs and GPR43 activation, further maintaining GLP-1 secretion. 
However, we did not observe the change in SCFAs and GPR43 activation due to the limited fund. In 
further study, the SCFAs and GPR43 activation should be explored. 
5. Conclusions 
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Based on the findings of this study, the a-LCD may be an effective intervention for the 
improvement of both depression and glycometabolism in patients with T2MD. A-LCD significantly 
increased the SCFAs-producing bacteria and maintained the GLP-1 secretion. We speculate that a-
LCD improving depression in T2DM patients may be associated with it stimulating the growth of 
SCFAs-producing bacteria, increasing SCFAs production and GPR43 activation, and further 
maintaining GLP-1 secretion. In futurestudies, the SCFAs and GPR43 activation should be further 
examined. 
6. Limitations 
There are several limitations of our study. One of the limitations is that the present study was 
conducted in a T2DM population with and without depression, which may limit the a-LCDeffect on 
depression. Further studies that examine the effects of a-LCD in patients with diabetes with clinical 
depression are required to understand the effectiveness of the current findings. We did not monitor 
the dynamic changes of depression over the three-month period; therefore, we could not find the 
earliest time point for improvement in depression. Due to the limitation of fund, the analysis method 
of gut microbiota needs to be improved in the further study. 
This will be taken into consideration in future research. 
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